Fertility and Sterility
Volume 91, Issue 2 , Pages 456-488, February 2009

The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report

  • Ricardo Azziz, M.D., M.P.H.

      Affiliations

    • Cedars-Sinai Medical Center and The David Geffen School of Medicine at UCLA, Los Angeles, California (Task Force Chair)
    • ,
  • Enrico Carmina, M.D.

      Affiliations

    • University of Palermo, Palermo, Italy
    • Corresponding Author InformationReprint requests: Enrico Carmina, M.D., Department of Clinical Medicine, University of Palermo, via delle Croci 47, 90139 Palermo, Italy (FAX: +39-091-655-5995).
    • ,
  • Didier Dewailly, M.D.

      Affiliations

    • Lille University Hospital, Lille, France
    • ,
  • Evanthia Diamanti-Kandarakis, M.D.

      Affiliations

    • University of Athens Medical School, Athens, Greece
    • ,
  • Héctor F. Escobar-Morreale, M.D., Ph.D.

      Affiliations

    • Hospital Ramon y Cajal, Madrid, Spain
    • ,
  • Walter Futterweit, M.D.

      Affiliations

    • Mount Sinai School of Medicine, New York, New York
    • ,
  • Onno E. Janssen, M.D.

      Affiliations

    • University of Essen, Essen, Germany
    • ,
  • Richard S. Legro, M.D.

      Affiliations

    • Pennsylvania State University School of Medicine, Hershey, Pennsylvania
    • ,
  • Robert J. Norman, M.D.

      Affiliations

    • University of Adelaide, Adelaide, Australia
    • ,
  • Ann E. Taylor

      Affiliations

    • Novartis, Cambridge, Massachusetts
    • ,
  • Selma F. Witchel, M.D.

      Affiliations

    • Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • (Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society)

      Affiliations

    • Formerly the Androgen Excess Society.

Received 12 February 2008; received in revised form 19 June 2008; accepted 23 June 2008. published online 23 October 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 R.A. is a consultant for drug development at Proctor & Gamble. E.C. has nothing to disclose. D.D. has nothing to disclose. E.D.-K. has nothing to declare. H.F.E.-M. has nothing to disclose. W.F. has nothing to disclose. O.E.J. has nothing to disclose. R.S.L. is a consultant for Glaxo Smith Kline, Ferring, Quat. Rx, Organon, Serono, and Solvay. R.J.N. has nothing to disclose. A.E.T. is an employee of Novartis. S.F.W. has nothing to disclose.

PII: S0015-0282(08)01392-7

doi:10.1016/j.fertnstert.2008.06.035

Fertility and Sterility
Volume 91, Issue 2 , Pages 456-488, February 2009

Article Tools

* Image Usage & Resolution